Lung Cancer Clinical Research Studies

PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies

Modular Phase 2 Study to Link Combination Immune-therapy to Patients With Advanced Solid and Hematologic Malignancies. Module 9: PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies.

Status: Enrolling
Updated: 12/31/1969

University of Wisconsin Hospital and Clinics

mi

from

Madison, WI

PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies

Modular Phase 2 Study to Link Combination Immune-therapy to Patients With Advanced Solid and Hematologic Malignancies. Module 9: PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies.

Status: Enrolling
Updated: 12/31/1969

California Pacific Medical Center Drug Shipment (2)

mi

from

San Francisco, CA

PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies

Modular Phase 2 Study to Link Combination Immune-therapy to Patients With Advanced Solid and Hematologic Malignancies. Module 9: PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies.

Status: Enrolling
Updated: 12/31/1969

Hematology Oncology Associates of Treasure Coast

mi

from

Port Saint Lucie, FL

PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies

Modular Phase 2 Study to Link Combination Immune-therapy to Patients With Advanced Solid and Hematologic Malignancies. Module 9: PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies.

Status: Enrolling
Updated: 12/31/1969

Northwestern University Med School

mi

from

Chicago, IL

PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies

Modular Phase 2 Study to Link Combination Immune-therapy to Patients With Advanced Solid and Hematologic Malignancies. Module 9: PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies.

Status: Enrolling
Updated: 12/31/1969

University of Illinois Cancer Center at Chicago SC

mi

from

Chicago, IL

PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies

Modular Phase 2 Study to Link Combination Immune-therapy to Patients With Advanced Solid and Hematologic Malignancies. Module 9: PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies.

Status: Enrolling
Updated: 12/31/1969

Indiana University

mi

from

Indianapolis, IN

PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies

Modular Phase 2 Study to Link Combination Immune-therapy to Patients With Advanced Solid and Hematologic Malignancies. Module 9: PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies.

Status: Enrolling
Updated: 12/31/1969

University of Kansas Clinical Research Center

mi

from

Fairway, KA

PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies

Modular Phase 2 Study to Link Combination Immune-therapy to Patients With Advanced Solid and Hematologic Malignancies. Module 9: PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies.

Status: Enrolling
Updated: 12/31/1969

Weinberg Cancer Institute at Franklin Square Hospital

mi

from

Baltimore, MD

PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies

Modular Phase 2 Study to Link Combination Immune-therapy to Patients With Advanced Solid and Hematologic Malignancies. Module 9: PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies.

Status: Enrolling
Updated: 12/31/1969

Oncology Hematology West, PC dba Nebraska Cancer Specialists

mi

from

Omaha, NE

PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies

Modular Phase 2 Study to Link Combination Immune-therapy to Patients With Advanced Solid and Hematologic Malignancies. Module 9: PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies.

Status: Enrolling
Updated: 12/31/1969

Comprehensive Cancer Centers

mi

from

Las Vegas, NV

PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies

Modular Phase 2 Study to Link Combination Immune-therapy to Patients With Advanced Solid and Hematologic Malignancies. Module 9: PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies.

Status: Enrolling
Updated: 12/31/1969

Providence Regional Cancer System SC

mi

from

Lacey, WA

PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies

Modular Phase 2 Study to Link Combination Immune-therapy to Patients With Advanced Solid and Hematologic Malignancies. Module 9: PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies.

Status: Enrolling
Updated: 12/31/1969

Oregon Health and Science University

mi

from

Portland, OR

PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies

Modular Phase 2 Study to Link Combination Immune-therapy to Patients With Advanced Solid and Hematologic Malignancies. Module 9: PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies.

Status: Enrolling
Updated: 12/31/1969

Medical College of Wisconsin

mi

from

Milwaukee, WI

PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies

Modular Phase 2 Study to Link Combination Immune-therapy to Patients With Advanced Solid and Hematologic Malignancies. Module 9: PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies.

Status: Enrolling
Updated: 12/31/1969

Billings Clinic Dept of Billings Clinic(2)

mi

from

Billings, MT

Study of Antibody Drug Conjugate in Patients With Advanced Breast Cancer Expressing HER2

A Phase 1b, First-in-Human, Dose Escalation and Expansion Study of XMT-1522 in Patients With Advanced Breast Cancer and Other Advanced Tumors Expressing HER2

Status: Enrolling
Updated: 12/31/1969

Moffitt Cancer Center

mi

from

Tampa, FL

Study of Antibody Drug Conjugate in Patients With Advanced Breast Cancer Expressing HER2

A Phase 1b, First-in-Human, Dose Escalation and Expansion Study of XMT-1522 in Patients With Advanced Breast Cancer and Other Advanced Tumors Expressing HER2

Status: Enrolling
Updated: 12/31/1969

Massachusetts General Hospital

mi

from

Boston, MA

Study of Antibody Drug Conjugate in Patients With Advanced Breast Cancer Expressing HER2

A Phase 1b, First-in-Human, Dose Escalation and Expansion Study of XMT-1522 in Patients With Advanced Breast Cancer and Other Advanced Tumors Expressing HER2

Status: Enrolling
Updated: 12/31/1969

Sarah Cannon Research Institute

mi

from

Nashville, TN

Study of Antibody Drug Conjugate in Patients With Advanced Breast Cancer Expressing HER2

A Phase 1b, First-in-Human, Dose Escalation and Expansion Study of XMT-1522 in Patients With Advanced Breast Cancer and Other Advanced Tumors Expressing HER2

Status: Enrolling
Updated: 12/31/1969

Mary Crowley Cancer Research Center

mi

from

Dallas, TX

Study of Antibody Drug Conjugate in Patients With Advanced Breast Cancer Expressing HER2

A Phase 1b, First-in-Human, Dose Escalation and Expansion Study of XMT-1522 in Patients With Advanced Breast Cancer and Other Advanced Tumors Expressing HER2

Status: Enrolling
Updated: 12/31/1969

South Texas Accelerated Research Therapeutics

mi

from

San Antonio, TX

Study of Nintedanib Plus Bevacizumab in Advanced Solid Tumors

Phase I Dose Escalation Study of Nintedanib Plus Bevacizumab in Advanced Solid Tumors

Status: Enrolling
Updated: 12/31/1969

University of Alabama at Birmingham, Comprehensive Cancer Center

mi

from

Birmingham, AL

Radiation Therapy With Combination Immunotherapy for Relapsed/Refractory Metastatic Melanoma

A Phase 1b/2 Study of Hypofractionated Radiation and Combination Immunotherapy for Relapsed/Refractory Metastatic Melanoma

Status: Enrolling
Updated: 12/31/1969

Masonic Cancer Center at University of Minnesota

mi

from

Minneapolis, MN

Mesothelin-Targeted Immunotoxin LMB-100 in Combination With SEL-110 in Subjects With Malignant Pleural or Peritoneal Mesothelioma

A Phase I Study of the Mesothelin-Targeted Immunotoxin LMB-100 in Combination With SEL-110 in Subjects With Malignant Pleural or Peritoneal Mesothelioma

Status: Enrolling
Updated: 12/31/1969

National Institutes of Health Clinical Center

mi

from

Bethesda, MD

Ph 1 Study in Subjects With Tumors Requiring Arginine to Assess ADI-PEG 20 With Pemetrexed and Cisplatin

Phase 1 Study in Subjects With Tumors Requiring Arginine to Assess ADI-PEG 20 With Pemetrexed and Cisplatin (ADIPemCis) (TRAP Study)

Status: Enrolling
Updated: 12/31/1969

Mayo Clinic Rochester

mi

from

Rochester, MN

Ph 1 Study in Subjects With Tumors Requiring Arginine to Assess ADI-PEG 20 With Pemetrexed and Cisplatin

Phase 1 Study in Subjects With Tumors Requiring Arginine to Assess ADI-PEG 20 With Pemetrexed and Cisplatin (ADIPemCis) (TRAP Study)

Status: Enrolling
Updated: 12/31/1969

Centre for Experimental Cancer Medicine (CECM)

mi

from

London,

Phase 1/2 Study of Ensartinib and Durvalumab, in ALK-rearranged Non-small Cell Lung Cancer

A Phase 1/2 Study of ALK Inhibitor, Ensartinib (X-396), and Anti-PD-L1, Durvalumab (MEDI4736), in Subjects With ALK-rearranged (ALK-positive) Non-small Cell Lung Cancer (NSCLC)

Status: Enrolling
Updated: 12/31/1969

Research Facility

mi

from

New York, NY

Trial of Measles Virotherapy in Combination With Atezolizumab in Patients With Metastatic Non-Small Cell Lung Cancer

Phase 1 Dose Escalation Trial of Intra-Tumoral Injection of Sodium Iodide Simporter (NIS) Measles Virus (Edmonston Strain) in Combination With Atezolizumab in Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC)

Status: Enrolling
Updated: 12/31/1969

The Mayo Clinic

mi

from

Rochester, MN

Study Evaluating the Safety of Rovalpituzumab Tesirine for Third-Line and Later Treatment of Subjects With Relapsed or Refractory Small Cell Lung Cancer

Open-Label, Single Arm, Phase 3b Study Evaluating the Safety of Rovalpituzumab Tesirine for Third-Line and Later Treatment of Subjects With Relapsed or Refractory DLL3 Expressing Small Cell Lung Cancer

Status: Enrolling
Updated: 12/31/1969

Ironwood Cancer & Res Ctr /ID# 171335

mi

from

Chandler, AZ

Study Evaluating the Safety of Rovalpituzumab Tesirine for Third-Line and Later Treatment of Subjects With Relapsed or Refractory Small Cell Lung Cancer

Open-Label, Single Arm, Phase 3b Study Evaluating the Safety of Rovalpituzumab Tesirine for Third-Line and Later Treatment of Subjects With Relapsed or Refractory DLL3 Expressing Small Cell Lung Cancer

Status: Enrolling
Updated: 12/31/1969

Mayo Clinic - Scottsdale /ID# 171359

mi

from

Scottsdale, AZ

Study Evaluating the Safety of Rovalpituzumab Tesirine for Third-Line and Later Treatment of Subjects With Relapsed or Refractory Small Cell Lung Cancer

Open-Label, Single Arm, Phase 3b Study Evaluating the Safety of Rovalpituzumab Tesirine for Third-Line and Later Treatment of Subjects With Relapsed or Refractory DLL3 Expressing Small Cell Lung Cancer

Status: Enrolling
Updated: 12/31/1969

VA Central California Health C /ID# 170951

mi

from

Fresno, CA

Study Evaluating the Safety of Rovalpituzumab Tesirine for Third-Line and Later Treatment of Subjects With Relapsed or Refractory Small Cell Lung Cancer

Open-Label, Single Arm, Phase 3b Study Evaluating the Safety of Rovalpituzumab Tesirine for Third-Line and Later Treatment of Subjects With Relapsed or Refractory DLL3 Expressing Small Cell Lung Cancer

Status: Enrolling
Updated: 12/31/1969

Loma Linda University Medical /ID# 171377

mi

from

Loma Linda, CA

Study Evaluating the Safety of Rovalpituzumab Tesirine for Third-Line and Later Treatment of Subjects With Relapsed or Refractory Small Cell Lung Cancer

Open-Label, Single Arm, Phase 3b Study Evaluating the Safety of Rovalpituzumab Tesirine for Third-Line and Later Treatment of Subjects With Relapsed or Refractory DLL3 Expressing Small Cell Lung Cancer

Status: Enrolling
Updated: 12/31/1969

UC Irvine Health /ID# 171343

mi

from

Orange, CA

Study Evaluating the Safety of Rovalpituzumab Tesirine for Third-Line and Later Treatment of Subjects With Relapsed or Refractory Small Cell Lung Cancer

Open-Label, Single Arm, Phase 3b Study Evaluating the Safety of Rovalpituzumab Tesirine for Third-Line and Later Treatment of Subjects With Relapsed or Refractory DLL3 Expressing Small Cell Lung Cancer

Status: Enrolling
Updated: 12/31/1969

Kaiser Permanente - Roseville /ID# 200779

mi

from

Roseville, CA

Study Evaluating the Safety of Rovalpituzumab Tesirine for Third-Line and Later Treatment of Subjects With Relapsed or Refractory Small Cell Lung Cancer

Open-Label, Single Arm, Phase 3b Study Evaluating the Safety of Rovalpituzumab Tesirine for Third-Line and Later Treatment of Subjects With Relapsed or Refractory DLL3 Expressing Small Cell Lung Cancer

Status: Enrolling
Updated: 12/31/1969

Kaiser Permanente-Santa Clara /ID# 203024

mi

from

Santa Clara, CA

Study Evaluating the Safety of Rovalpituzumab Tesirine for Third-Line and Later Treatment of Subjects With Relapsed or Refractory Small Cell Lung Cancer

Open-Label, Single Arm, Phase 3b Study Evaluating the Safety of Rovalpituzumab Tesirine for Third-Line and Later Treatment of Subjects With Relapsed or Refractory DLL3 Expressing Small Cell Lung Cancer

Status: Enrolling
Updated: 12/31/1969

Kaiser Permanente Medical Ctr-Vallejo /ID# 169758

mi

from

Vallejo, CA

Study Evaluating the Safety of Rovalpituzumab Tesirine for Third-Line and Later Treatment of Subjects With Relapsed or Refractory Small Cell Lung Cancer

Open-Label, Single Arm, Phase 3b Study Evaluating the Safety of Rovalpituzumab Tesirine for Third-Line and Later Treatment of Subjects With Relapsed or Refractory DLL3 Expressing Small Cell Lung Cancer

Status: Enrolling
Updated: 12/31/1969

Kaiser Permanente- Walnut Creek /ID# 201305

mi

from

Walnut Creek, CA

Study Evaluating the Safety of Rovalpituzumab Tesirine for Third-Line and Later Treatment of Subjects With Relapsed or Refractory Small Cell Lung Cancer

Open-Label, Single Arm, Phase 3b Study Evaluating the Safety of Rovalpituzumab Tesirine for Third-Line and Later Treatment of Subjects With Relapsed or Refractory DLL3 Expressing Small Cell Lung Cancer

Status: Enrolling
Updated: 12/31/1969

Univ of Colorado Cancer Center /ID# 200810

mi

from

Aurora, CO

Study Evaluating the Safety of Rovalpituzumab Tesirine for Third-Line and Later Treatment of Subjects With Relapsed or Refractory Small Cell Lung Cancer

Open-Label, Single Arm, Phase 3b Study Evaluating the Safety of Rovalpituzumab Tesirine for Third-Line and Later Treatment of Subjects With Relapsed or Refractory DLL3 Expressing Small Cell Lung Cancer

Status: Enrolling
Updated: 12/31/1969

Boca Raton Regional Hospital /ID# 200168

mi

from

Boca Raton, FL

Study Evaluating the Safety of Rovalpituzumab Tesirine for Third-Line and Later Treatment of Subjects With Relapsed or Refractory Small Cell Lung Cancer

Open-Label, Single Arm, Phase 3b Study Evaluating the Safety of Rovalpituzumab Tesirine for Third-Line and Later Treatment of Subjects With Relapsed or Refractory DLL3 Expressing Small Cell Lung Cancer

Status: Enrolling
Updated: 12/31/1969

UMHC/Sylvester Comprehensive /ID# 171462

mi

from

Deerfield Beach, FL

Study Evaluating the Safety of Rovalpituzumab Tesirine for Third-Line and Later Treatment of Subjects With Relapsed or Refractory Small Cell Lung Cancer

Open-Label, Single Arm, Phase 3b Study Evaluating the Safety of Rovalpituzumab Tesirine for Third-Line and Later Treatment of Subjects With Relapsed or Refractory DLL3 Expressing Small Cell Lung Cancer

Status: Enrolling
Updated: 12/31/1969

Mount Sinai Comp Cancer Ctr /ID# 169759

mi

from

Miami, FL

Study Evaluating the Safety of Rovalpituzumab Tesirine for Third-Line and Later Treatment of Subjects With Relapsed or Refractory Small Cell Lung Cancer

Open-Label, Single Arm, Phase 3b Study Evaluating the Safety of Rovalpituzumab Tesirine for Third-Line and Later Treatment of Subjects With Relapsed or Refractory DLL3 Expressing Small Cell Lung Cancer

Status: Enrolling
Updated: 12/31/1969

Illinois Cancer Care, PC /ID# 171310

mi

from

Peoria, IL

Study Evaluating the Safety of Rovalpituzumab Tesirine for Third-Line and Later Treatment of Subjects With Relapsed or Refractory Small Cell Lung Cancer

Open-Label, Single Arm, Phase 3b Study Evaluating the Safety of Rovalpituzumab Tesirine for Third-Line and Later Treatment of Subjects With Relapsed or Refractory DLL3 Expressing Small Cell Lung Cancer

Status: Enrolling
Updated: 12/31/1969

Baptist Health /ID# 171379

mi

from

Lexington, KY

Study Evaluating the Safety of Rovalpituzumab Tesirine for Third-Line and Later Treatment of Subjects With Relapsed or Refractory Small Cell Lung Cancer

Open-Label, Single Arm, Phase 3b Study Evaluating the Safety of Rovalpituzumab Tesirine for Third-Line and Later Treatment of Subjects With Relapsed or Refractory DLL3 Expressing Small Cell Lung Cancer

Status: Enrolling
Updated: 12/31/1969

Norton Cancer Institute /ID# 200827

mi

from

Louisville, KY

Study Evaluating the Safety of Rovalpituzumab Tesirine for Third-Line and Later Treatment of Subjects With Relapsed or Refractory Small Cell Lung Cancer

Open-Label, Single Arm, Phase 3b Study Evaluating the Safety of Rovalpituzumab Tesirine for Third-Line and Later Treatment of Subjects With Relapsed or Refractory DLL3 Expressing Small Cell Lung Cancer

Status: Enrolling
Updated: 12/31/1969

Tulane Cancer Center Clinic /ID# 171376

mi

from

New Orleans, LA

Study Evaluating the Safety of Rovalpituzumab Tesirine for Third-Line and Later Treatment of Subjects With Relapsed or Refractory Small Cell Lung Cancer

Open-Label, Single Arm, Phase 3b Study Evaluating the Safety of Rovalpituzumab Tesirine for Third-Line and Later Treatment of Subjects With Relapsed or Refractory DLL3 Expressing Small Cell Lung Cancer

Status: Enrolling
Updated: 12/31/1969

Sandra Malcolm Berman Cncr Ins /ID# 171346

mi

from

Baltimore, MD

Study Evaluating the Safety of Rovalpituzumab Tesirine for Third-Line and Later Treatment of Subjects With Relapsed or Refractory Small Cell Lung Cancer

Open-Label, Single Arm, Phase 3b Study Evaluating the Safety of Rovalpituzumab Tesirine for Third-Line and Later Treatment of Subjects With Relapsed or Refractory DLL3 Expressing Small Cell Lung Cancer

Status: Enrolling
Updated: 12/31/1969

St. Luke's University Hospital /ID# 171374

mi

from

Duluth, MN

Study Evaluating the Safety of Rovalpituzumab Tesirine for Third-Line and Later Treatment of Subjects With Relapsed or Refractory Small Cell Lung Cancer

Open-Label, Single Arm, Phase 3b Study Evaluating the Safety of Rovalpituzumab Tesirine for Third-Line and Later Treatment of Subjects With Relapsed or Refractory DLL3 Expressing Small Cell Lung Cancer

Status: Enrolling
Updated: 12/31/1969

Valley Hospital - Westwood, NJ /ID# 171357

mi

from

Westwood, NJ

Study Evaluating the Safety of Rovalpituzumab Tesirine for Third-Line and Later Treatment of Subjects With Relapsed or Refractory Small Cell Lung Cancer

Open-Label, Single Arm, Phase 3b Study Evaluating the Safety of Rovalpituzumab Tesirine for Third-Line and Later Treatment of Subjects With Relapsed or Refractory DLL3 Expressing Small Cell Lung Cancer

Status: Enrolling
Updated: 12/31/1969

Wake Forest Baptist Medical Center /ID# 169799

mi

from

Winston-Salem, NC

Study Evaluating the Safety of Rovalpituzumab Tesirine for Third-Line and Later Treatment of Subjects With Relapsed or Refractory Small Cell Lung Cancer

Open-Label, Single Arm, Phase 3b Study Evaluating the Safety of Rovalpituzumab Tesirine for Third-Line and Later Treatment of Subjects With Relapsed or Refractory DLL3 Expressing Small Cell Lung Cancer

Status: Enrolling
Updated: 12/31/1969

The Ohio State University Comp /ID# 171352

mi

from

Columbus, OH

Study Evaluating the Safety of Rovalpituzumab Tesirine for Third-Line and Later Treatment of Subjects With Relapsed or Refractory Small Cell Lung Cancer

Open-Label, Single Arm, Phase 3b Study Evaluating the Safety of Rovalpituzumab Tesirine for Third-Line and Later Treatment of Subjects With Relapsed or Refractory DLL3 Expressing Small Cell Lung Cancer

Status: Enrolling
Updated: 12/31/1969

St. Luke's Hematology Oncology /ID# 171378

mi

from

Bethlehem, PA

Study Evaluating the Safety of Rovalpituzumab Tesirine for Third-Line and Later Treatment of Subjects With Relapsed or Refractory Small Cell Lung Cancer

Open-Label, Single Arm, Phase 3b Study Evaluating the Safety of Rovalpituzumab Tesirine for Third-Line and Later Treatment of Subjects With Relapsed or Refractory DLL3 Expressing Small Cell Lung Cancer

Status: Enrolling
Updated: 12/31/1969

Tennessee Oncology PLLC: Sarah /ID# 171380

mi

from

Nashville, TN

Clinical Research Trials Archive – Closed Trials

Zip code

Condition

We've found

35,033

archived clinical trials in

Lung Cancer

Clinical Research Trials Archive – Closed Trials

Zip code

Condition

We've found 35,033 archived clinical trials in Lung Cancer

Select your condition

Common Conditions

All Conditions

We've found

35,033

archived clinical trials in

Lung Cancer